Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1998 1
1999 1
2002 3
2003 1
2004 5
2005 2
2006 1
2007 2
2009 1
2010 1
2011 4
2012 2
2013 1
2014 3
2017 2
2018 4
2019 1
2020 2
2022 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Matikas A, Möbus V, Greil R, Andersson A, Steger GG, Untch M, Fornander T, Malmström P, Schmatloch S, Johansson H, Hellström M, Brandberg Y, Gnant M, Loibl S, Foukakis T, Bergh J; SweBCG, ABCSG and GBG. Matikas A, et al. J Clin Oncol. 2024 Sep 10;42(26):3077-3082. doi: 10.1200/JCO.24.00178. Epub 2024 Jul 17. J Clin Oncol. 2024. PMID: 39018515 Free PMC article. Clinical Trial.
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, Tanner M, Ahlgren J, Auvinen P, Lahdenperä O, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Bono P, Junnila J, Lindman H. Joensuu H, et al. Among authors: villman k. J Clin Oncol. 2022 Apr 1;40(10):1051-1058. doi: 10.1200/JCO.21.02054. Epub 2022 Jan 12. J Clin Oncol. 2022. PMID: 35020465 Free PMC article. Clinical Trial.
Reply to a. Levy et Al.
Wickberg A, Holmberg L, Adami HO, Magnuson A, Villman K, Liljegren G. Wickberg A, et al. Among authors: villman k. J Clin Oncol. 2014 Oct 10;32(29):3340. doi: 10.1200/JCO.2014.56.8493. Epub 2014 Aug 25. J Clin Oncol. 2014. PMID: 25154817 No abstract available.
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.
Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Villman KK, Halonen P, Granstam-Björneklett H, Tanner M, Sailas L, Turpeenniemi-Hujanen T, Yachnin J, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H. Joensuu H, et al. Among authors: villman kk. JAMA Netw Open. 2024 Aug 1;7(8):e2429772. doi: 10.1001/jamanetworkopen.2024.29772. JAMA Netw Open. 2024. PMID: 39186271 Free article. Clinical Trial.
Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Wu Q, et al. Among authors: villman k. Pathol Oncol Res. 2004;10(1):26-33. doi: 10.1007/BF02893405. Epub 2004 Mar 18. Pathol Oncol Res. 2004. PMID: 15029258 Free article.
37 results